Surrozen, Inc. (SRZN) DCF Valuation

Surrozen, Inc. (SRZN) DCF -Bewertung

US | Healthcare | Biotechnology | NASDAQ
Surrozen, Inc. (SRZN) DCF Valuation

Fully Editable: Tailor To Your Needs In Excel Or Sheets

Professional Design: Trusted, Industry-Standard Templates

Investor-Approved Valuation Models

MAC/PC Compatible, Fully Unlocked

No Expertise Is Needed; Easy To Follow

Surrozen, Inc. (SRZN) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Verbessern Sie Ihre Investitionsauswahl mit dem DCF -Taschenrechner von Surrozen, Inc. (SRZN)! Erforschen Sie reale Finanzdaten für Surrozen, passen Sie Wachstumsprojektionen und -kosten an und sehen Sie sofort, wie sich diese Anpassungen auf den inneren Wert von Surrozen, Inc. (SRZN) auswirken.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue .0 .0 12.5 .0 10.7 8.0 6.0 4.5 3.4 2.5
Revenue Growth, % 0 0 0 -100 0 -25 -25 -25 -25 -25
EBITDA -31.4 -51.4 -42.4 -41.1 -25.5 1.6 1.2 .9 .7 .5
EBITDA, % 100 100 -339.07 100 -239.69 20 20 20 20 20
Depreciation 2.9 3.3 3.3 1.9 .0 5.2 3.9 2.9 2.2 1.6
Depreciation, % 100 100 26.15 100 0 65.23 65.23 65.23 65.23 65.23
EBIT -34.3 -54.6 -45.7 -43.0 -25.5 1.6 1.2 .9 .7 .5
EBIT, % 100 100 -365.22 100 -239.69 20 20 20 20 20
Total Cash 49.2 101.9 75.8 36.0 34.6 8.0 6.0 4.5 3.4 2.5
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 2.0 2.2 2.5
Account Receivables, % 100 100 15.82 100 23.85
Inventories .0 .0 .0 .0 .0 4.8 3.6 2.7 2.0 1.5
Inventories, % 100 100 0 100 0 60 60 60 60 60
Accounts Payable 1.8 2.7 .7 .5 .3 4.9 3.7 2.8 2.1 1.6
Accounts Payable, % 100 100 5.26 100 2.87 61.63 61.63 61.63 61.63 61.63
Capital Expenditure -.9 -1.3 -.7 -.4 .0 -.1 -.1 -.1 .0 .0
Capital Expenditure, % 100 100 -5.82 100 -0.24402 -1.21 -1.21 -1.21 -1.21 -1.21
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -34.2 -52.5 -35.1 -43.0 -25.5 1.5 1.1 .8 .6 .5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -30.4 -49.5 -36.6 -41.8 -26.2 3.6 6.3 4.7 3.5 2.7
WACC, % 6.39 6.36 6.19 6.39 6.39 6.35 6.35 6.35 6.35 6.35
PV UFCF
SUM PV UFCF 17.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 3
Terminal Value 62
Present Terminal Value 46
Enterprise Value 63
Net Debt -26
Equity Value 89
Diluted Shares Outstanding, MM 3
Equity Value Per Share 30.50

What You Will Gain

  • Comprehensive Financial Model: Surrozen’s actual data facilitates accurate DCF valuation.
  • Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential variables.
  • Real-Time Calculations: Immediate updates ensure you view results as adjustments are made.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Adaptable and Repeatable: Designed for versatility, allowing for ongoing use in detailed forecasting.

Key Features

  • Real-Life SRZN Data: Pre-filled with Surrozen’s historical financials and future projections.
  • Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures as needed.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
  • Scenario Testing: Develop various forecast scenarios to evaluate different valuation possibilities.
  • User-Friendly Design: Intuitive, organized, and suitable for both professionals and newcomers.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Surrozen, Inc. (SRZN)'s preloaded data.
  • 2. Adjust Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures relevant to Surrozen, Inc. (SRZN).
  • 3. View Results Instantly: The DCF model automatically calculates the intrinsic value and NPV for Surrozen, Inc. (SRZN).
  • 4. Explore Scenarios: Analyze various forecasts to assess different valuation outcomes for Surrozen, Inc. (SRZN).
  • 5. Present with Confidence: Share professional valuation insights for Surrozen, Inc. (SRZN) to bolster your decision-making process.

Why Choose This Calculator for Surrozen, Inc. (SRZN)?

  • Designed for Experts: A specialized tool utilized by investors, analysts, and biotech consultants.
  • Accurate Data: Surrozen’s historical and projected financials are preloaded for precise analysis.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Step-by-step guidance ensures a smooth calculation process.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and accurate valuation models for analyzing Surrozen, Inc. (SRZN) stock.
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
  • Consultants and Advisors: Deliver precise valuation insights to clients regarding Surrozen, Inc. (SRZN).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
  • Biotechnology Enthusiasts: Gain insights into how biotech companies like Surrozen, Inc. (SRZN) are valued in the market.

What the Surrozen, Inc. (SRZN) Template Contains

  • Pre-Filled Data: Includes Surrozen’s historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
  • Key Financial Ratios: Assess Surrozen’s profitability, efficiency, and leverage metrics.
  • Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
  • Clear Dashboard: Visuals and tables summarizing essential valuation outcomes.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.